Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samsung Biologics Sees Biosimilars As One Of Three Key Pillars

Follows Deal To Take Full Ownership Of Samsung Bioepis From Biogen

Executive Summary

Samsung Biologics has reiterated the importance of biosimilars to its business in the wake of its move to buy out partner Biogen’s stake in their Samsung Bioepis biosimilars joint venture.

You may also be interested in...



Alvotech Makes It Four With Denosumab Trial

Alvotech has begun its fourth biosimilar clinical trial program, announcing the start of studies for its AVT03 proposed denosumab rival to Prolia/Xgeva.

Shilpa Medicare’s Plan For Eylea Biosimilar Spells Ambition, But Path Not Easy

Shilpa Medicare’s plan for trials of an Eylea biosimilar shows the company’s ambition to leapfrog to a biosimilars-led growth strategy, one that Indian majors like Cipla and Lupin pivoted to post a successful generics program. However, the path isn’t going to be easy and Biocon/Viatris, Samsung Biologics are ahead

Biogen Exits Joint Venture As Samsung Biologics Buys Out Bioepis

Biogen’s stake in Samsung Bioepis has been fully acquired by former partner Samsung Biologics, following an announcement of the deal in January.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel